Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The best anti-HIV treatment regimen for pregnant women is not known. Protease inhibitors
(PIs) are often used, but they have side effects that may be harmful for pregnant women. It
is not known if treatment regimens that do not include PIs are as effective in pregnant women
as those that include PIs. This trial will compare two anti-HIV treatment plans, one with and
one without PIs, in women who start HIV treatment during pregnancy. The study will evaluate
the effects of the anti-HIV drugs on the developing infant and prevention of mother-to-child
HIV transmission during pregnancy.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
HIV Protease Inhibitors Lamivudine Lamivudine, zidovudine drug combination Nelfinavir Nevirapine Protease Inhibitors Zidovudine